Drugs / rF-gp100P209
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00080353 | Mar 2004 → Dec 2007 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rF-gp100P209 | “immunization with intravenous fowlpox virus rF-gp100P209” NCT00080353 ↗ |
| Modality | Vaccine | “an experimental vaccine called fowlpox gp100” NCT00080353 ↗ |
| Route | Intravenous | “intravenous fowlpox virus rF-gp100P209” NCT00080353 ↗ |